Springer Health+ IME
@SpringerIME
Springer Health+ IME, providing independent medical education in Neurology, Diabetes, Oncology, Rare Diseases, Endocrinology, and Paediatrics.
加入 March 2016
2.8K 正在關注 19.8K 粉絲
New phase 2 trial findings published in The Lancet Diabetes & Endocrinology suggest burosumab treatment for X-linked hypophosphataemia (XLH) may begin in the first year of life. Unpick the findings in our latest article.
顯示更多
